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Summary
Patients requiring transfusion medicine and hemother-
apy in an inpatient setting are incorporated into the Ger-
man Diagnosis Related Groups (G-DRG) system in multi-
ple ways. Different DRGs exist in Major Diagnostic Cate-
gory 16 for patients that have been admitted for the 
treatment of a condition from the field of transfusion 
medicine. However, the reimbursement might be not 
cost covering for many cases, and efforts have to be in-
tensified to find adequate definitions and prices. We be-
lieve that this can only be successful if health service re-
search is intensified in this field. For patients requiring 
hemotherapy and transfusion medicine concomitant to 
the treatment of an underlying disease such as cancer, 
multiple systems exist to increase remuneration, among 
them the Patient Clinical Complexity Level (PCCL) and 
complex constellations to induce DRG splits. For direct 
reimbursement of high cost products, additional remu-
neration fees (Zusatzentgelte, ZE) are the most impor-
tant. In addition, expensive innovations not reflected 
within the DRGs can be reimbursed after application and 
negotiation of the New Diagnostic and Treatment Meth-
ods (Neue Untersuchungs- und Behandlungsmethoden, 
NUB) system. The NUB system guarantees that medical 
progress is put rapidly into clinical practice and prevents 
financial issues from becoming a stumbling block for the 
use of innovative drugs and methods. 
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Zusammenfassung
Patienten, die eine stationäre transfusionsmedizinische 
und hämotherapeutische Behandlung erfordern, sind in 
verschiedener Weise in das System der Diagnosebezoge-
nen Fallgruppen (German Diagnosis Related Groups, G-
DRGs) inkorporiert. Die Major Diagnostic Category 16 
enthält verschiedene DRGs für Patienten, die zur Be-
handlung einer Erkrankung aus dem Bereich der Trans-
fusionsmedizin stationär aufgenommen werden. In vie-
len Fällen deckt die Kostenerstattung jedoch nicht die 
eigentlichen Kosten, weshalb verstärkt Anstrengungen 
unternommen werden müssen, adäquate Definitionen 
und Preise festzulegen. Wir sind der Meinung, dass dies 
nur auf der Basis einer intensiveren Forschung auf die-
sem Gebiet möglich ist. Für Patienten, die hämothera-
peutische und transfusionsmedizinische Maßnahmen 
begleitend zur Behandlung der zugrunde liegenden 
 Erkrankung (z.B. Krebs) benötigen, existieren verschie-
dene Systeme zur Aufstockung der Kostenerstattung. 
Dazu gehören der Patient Clinical Complexity Level 
(PCCL) sowie komplexe Konstellationen, die DRG-Splits 
zulassen. Für die direkte Erstattung von Kosten für sehr 
teure Produkte sind vor allem die Zusatzentgelte (ZE) 
bedeutsam. Zusätzlich können kostenaufwendige Inno-
vationen, die nicht in den DRGs enthalten sind, durch 
Anwendung und Übertragung des NUB(Neue Unter-
suchungs- und Behandlungsmethoden)-Systems gedeckt 
werden. Das NUB-System stellt sicher, dass medizini-
scher Fortschritt rasch in die klinische Praxis übertragen 
wird, und verhindert, dass finanzielle Fragestellungen 
die Anwendung innovativer Medikamente und Metho-
den behindern.
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sion 4.1, but has since continuously matured [9]. Today, with 
the 7th amendment in place, only the nomenclature reminds 
of the Australian predecessor: Alphabetic prefixes from A to 
Z mark the 24 Major Diagnostic Categories (MDC). These 
are categorized mainly by the anatomical location of the dis-
ease. Numbers from 00 to 99 address the DRG itself. Suffixes 
differentiate between DRG splits, with A usually representing 
the most expensive DRG. The alphabetic sequence of suffixes 
is variable and can reach counts from 1 (usually marked with 
Z) to 9 (from A down to I). 
The DRG finding process is automated, and only approved 
Grouper software is authorized. The MDC is mainly triggered 
by the so-called principal diagnosis. The principal diagnosis is 
defined in official guidelines as the diagnosis identified to be 
mainly responsible for the hospitalization of the patient [10]. 
The diagnosis is coded by use of the WHO International Clas-
sification of Diseases (ICD-10), German modification (ICD-
10 GM) [11]. 
Interventional services, and surgeries in particular, mainly 
push the case into more expensive DRGs within a MDC. 
Among the medical services, the DRGs are mainly split up by 
expenditures. Comorbidity is the major criteria to lead a case 
into a more expensive DRG split. Figure 1 shows the basic 
principle of the G-DRG system based on the example of 
DRG Q61E which is the most common DRG for patients 
being hospitalized for anaemia. 
DRGs are temporary, and so-called lower and upper trim 
points are defined for each DRG. Between the 2 trim points, 
a lump sum is paid regardless of the length of the hospital 
stay. Below the lower trim point, diurnal deductions have to 
be accepted. Beyond the upper trim point, per diem rates are 
added to the DRG lump sum remuneration, and again the 
amount of the per diem rate is DRG-specific (fig. 2). 
In 2005, with the introduction of the 2nd amendment of 
the G-DRG system, the authorities realized that a lump sum 
alone does not sufficiently cover expenses arising in patients 
Introduction
In modern medicine, blood and its components have become 
an indispensable product widely used in patients undergoing 
surgery, chemotherapy, transplantation, or obstetric and gy-
naecological procedures [1]. Among all German hospitals, 
more than 925,000 blood transfusions were documented in 
2007, and plasma products were used in more than 191,000 
cases [2]. In 2008, the numbers were 968,000 and 205,000, re-
spectively. Approximately 92–95% of blood is transfused in 
the inpatient setting [3]. Shrinking donor pools and stringent 
donor qualification criteria can lead to rising costs and con-
straints in the supply of blood products [4]. Although in gen-
eral only about 1% of the total inpatient treatment costs are 
caused by hemotherapy, this figure can substantially rise in 
patients requiring frequent transfusions such as in leukaemia 
treatment, organ transplantation, or obstetrics [5]. Therefore, 
it is important for hospitals to focus on optimal blood acquisi-
tion and to avoid inappropriate blood transfusions [6]. Nego-
tiating adequate reimbursement for transfusions is also a 
major concern for hospitals.
In Germany, the German Diagnosis Related Group (G-
DRG) lump sum system was introduced in 2003, and is up-
dated annually. This system was designed to be based on real 
cost data and to be self-adapting. All 2,087 German hospitals 
are obliged to transmit clinical data on all inpatient cases to 
the National Institute for the Hospital Remuneration System 
(Institut für das Entgeltsystem im Krankenhaus, InEK). Data 
include diagnoses, services, basic patient data, and the dura-
tion of hospitalization. Apart from this mandatory part, hospi-
tals have the option to supply accounting data. For the calcu-
lation of the 2010 G-DRG system, 253 hospitals provided data 
on 4.8 million cases, which included detailed information on 
the number of blood products transfused as well as accurate 
cost data, in particular costs of each blood product. G-DRG 
could best be compared to Medicare’s prospective payment 
system in the USA where also an annual process for updating 
exists which includes the pricing of the hospital market basket 
and the weighting of the DRGs [3, 7, 8].
This review focuses on the 2010 G-DRG system and ad-
dresses issues that are specific to hemotherapy: What tools do 
we need for adequate mapping of the costs in a lump sum sys-
tem? How can we try to adequately remunerate the treatment 
of a patient presenting with a diagnosis typical for transfusion 
medicine? How can we try to adequately remunerate the 
treatment of all patients presenting with diagnoses typical for 
transfusion medicine? 
Lump Sums and Additional Remuneration Fees Are 
the Backbone of the G-DRG System
The G-DRG system is mainly based on lump sums. It was de-
veloped on the basis of the Australian AR-DRG system ver-
Fig. 1. Basic princi-
ple of categorization 
in the G-DRG sys-
tem (MDC = Major 
diagnostic category; 
w/o = without).
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over 14 years of age and adults receiving 6–15 transfusions. A 
calculation of the per unit remuneration in table 1 shows that 
the average remuneration for 1 PRC in the G-DRG system 
depending on the rank within the table is around EUR 75.00 
per unit. This, however, applies only to adult patients receiv-
ing 16 or more transfusions. Therefore, costs for the first 15 
PRC transfusions have to be covered within the respective 
DRG. At the same time, it is very likely that the remunera-
tion for PRC transfusions in the G-DRG system does not 
cover the costs. Per unit blood transfusion costs shown in sys-
temic studies [12, 13] ranged from USD 332.00 to USD 717.00 
(adjusted for inflation), and newer studies say that even this 
price is inaccurate and misleading [14]. Newer activity-based 
analyses show that blood costs have been underestimated 
when only acquisition costs were taken into account. Shander 
et al. [14] calculated in a model considering all major process 
steps that 3.2–4.8-fold higher costs emerge (estimated RBC 
unit costs USD 761.00 ± USD 294.00). Since the G-DRG cost 
calculations are based on real life costs from hospital ac-
counting systems, the most plausible conclusion is that cost 
updates are flawed by the poor quality of hospital cost data. 
The same problem was observed in the USA where only 48% 
of the hospitals billed at all for blood-related costs in their 
cost report for Medicare [3]. These numbers clearly show 
that DRG remuneration will only be as good as the cost data 
provided. Hospitals must aspire to provide complete data, 
taking into account all costs associated with transfusion (not 
only acquisition costs), since this is the only way the DRG 
system can be optimized [15].
Challenge 1: Trying to Adequately Remunerate the 
Treatment of a Patient Presenting with a Principal  
Diagnosis Typical for Transfusion Medicine
The G-DRGs for hemotherapy and transfusion medicine 
have not changed significantly over time. A comparison of 
the DRGs in the MDC 16 (diseases of the blood, haema-
topoietic organs, and the immune system) shows that while 
during the 8 years of developing the G-DRG system the 
overall number of DRGs has increased considerably, the 
number of DRGs in MDC 16 has risen only modestly. 
G-DRG 2003 (version 1.0) was composed of 664 DRGs, 
among them 10 DRGs in MDC 16. 8 years later, G-DRG 
2010 consists of 1,200 DRGs, and in MDC 16 a total of 16 
DRGs can be found. The addition of almost 550 DRGs was 
done to assure adequate recovery of costs for most of pa-
tients, especially those with extremely high costs. Why MDC 
16 was not extended to the same degree, may have 1 of 2 rea-
sons: Either the quality of remuneration in MDC 16 was so 
good that there was no need for an adaptation, or the quality 
of the data used for calculation was so bad that the authori-
ties could not find enough characteristic factors to differenti-
ate the DRGs in another way. 
who require components so expensive that the costs far 
 exceed those usually found among a particular group of pa-
tients. This observation led to the introduction of additional 
remuneration fees (Zusatzentgelte, ZE) for components or 
services. The ZE are not designed to recover all acquisition 
costs for hemotherapy. The aim was to design an ‘airbag sys-
tem’ capable to hedge extreme costs. Table 1 displays the 
fees paid for the transfusion of packed red cells (PRC). No 
fee is paid for patients receiving 1–5 PRC transfusions, hence 
it is assumed that the costs are covered by the DRG lump 
sum remuneration itself. Also no fee is paid for adolescents 
Fig. 2. Typical pro-
gression of DRG 
lump sum remunera-
tion dependent on the 
length of hospitaliza-
tion; G-DRG 2010, 
base rate EUR 
2,935.00 (DRG Q61E. 
UGVD = Lower trim 
point (full DRG is 
paid after a 2-night 
stay); OGVD = upper 
trim point (a per diem rate is paid for the 13th night and beyond); LOH 
= length of hospitalization (nights)).
PRC transfusions, n Remuneration, EUR
  0–5 0.00
  6–10a 608.10
 11–15a 1,004.60
 16–23 1,480.50 
 24–31 2,115.00 
 32–39 2,749.40 
 40–47 3,383.90 
 48–55 4,018.40 
 56–63 4,652.90 
 64–71 5,287.40 
 72–79 5,921.90 
 80–87 6,556.40 
 88–103 7,402.30 
104–119 8,671.30 
120–135 9,940.30 
136–151 11,209.30 
152–167 12,478.20 
168–183 13,747.20 
184–199 15,016.20 
200–215 16,285.10 
216–231 17,554.10 
232–247 18,823.10 
248–263 20,092.10 
264–279 21,361.00 
280 and more 22,630.00 
aOnly for children below the age of 15 years.
Table 1. Additional 
remuneration fees 
(ZE) for packed red 
cells (PRC) in the 
2010 G-DRG system
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cost-covering at all. Indeed the funding gap was –24% overall, 
with Q61D at –55% and Q61A at –44% incurring the most 
dramatic losses. We believe that this discrepancy is due to a 
mixture of drug-induced aplastic anaemia accounting for the 
low cost cases (76% of cases put into the calculation) and se-
vere aplastic anaemia accounting for the high cost cases typi-
cally being treated at university hospitals (5% of cases). It 
may be possible that patients with severe aplastic anaemia 
should be allocated to the complex diagnosis group. 
Challenge 2: Trying to Adequately Remunerate  
the Treatment of All Patients Presenting with  
a Concomitant Diagnosis Typical for Transfusion  
Medicine
The majority of patients requiring transfusion medicine and 
hemotherapy do not visit the hospital due to a diagnosis pri-
marily from this field of medicine. In fact, the need for trans-
fusion is almost ubiquitous, and in almost all DRGs transfu-
sion can be found. In an analysis carried out in 60 university 
hospitals in the USA in 1995, Jefferies et al. [5] showed that 
471 of 486 DRGs had identifiable blood costs. The highest 
mean costs could be found in the DRG for bone marrow 
transplant (DRG 481) with USD 6,183.00, followed by liver 
transplant (DRG 480, USD 5,548.00) and acute leukaemia 
The G-DRG 2010 System Has 4 Central Trigger Points to 
Find the Correct DRG in MDC 16
Surgery in patients with a principal diagnosis eligible for 
MDC 16 is split up into 3 groups: splenectomy (DRG Q01), 
major surgery (DRG Q02), and minor surgery (DRG Q03) 
(fig. 3). Erythrocyte diseases are separated (DRG Q61) from 
the diseases of the immune system and coagulation disorders 
(DRG Q60). In both DRG Q60 and Q61, special diagnoses 
qualify for a more expensive DRG. In all mentioned DRGs, 
children are treated separately. 
Figure 4 visualizes the algorithm for the erythrocyte dis-
eases. Complex diagnoses are been guided to DRG Q61B al-
ways. Only few diagnoses have been classified as being com-
plex (table 2). Interestingly, further comorbidity is of no rele-
vance in patients with a complex diagnosis, and regardless of 
the comorbidity level (see also definition in the lower sec-
tions) all patients with complex diagnoses are always grouped 
to DRG Q61B. The second subgroup are patients with aplas-
tic anaemia (ICD-10 D61.-), and again all patients with this 
diagnosis are grouped to DRG Q61C or Q61D, respectively, 
without any focus on comorbidity. This results in a paradox: 
an adult patient with aplastic anaemia and a very high level of 
comorbidity is always allocated to DRG Q61D (revenue 
EUR 2,478.00) whereas EUR 3,680.00 would be paid if an-
other type of anaemia was described. This paradox is an indi-
cator for the immaturity of the DRG system with regard to 
MDC 16, even in its 8th generation. A comparison of the re-
imbursement level with the level of costs within MDC 16 re-
veals an even more dramatic result. An unpublished analysis 
of the German University Hospital Consortium (Verband der 
Universitätsklinika Deutschlands, VUD) showed for 10 uni-
versity hospitals that the medical DRGs Q60 and Q61 are not 
Fig. 3. MDC 16 – Surgical DRGs, simplified (base rate EUR 2,935.00).
Fig. 4. MDC 16 – Diseases of the Erythrocytes, simplified (base rate 
EUR 2,935.00).
Table 2. Complex diagnoses eligible for DRG Q61B
Vitamin B12 deficiency anaemia (ICD D51.-)
Sickle cell anaemia with crisis (ICD D57.0)
Drug-induced autoimmune haemolytic anaemia (ICD D59.0)
Other autoimmune haemolytic anaemia (ICD D59.1)
ABO incompatibility reaction (ICD T80.3)
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defined combination of different procedure codes; iii) Proce-
dures may be directly remunerated by ZE.
A patient’s level of comorbidity and complexity (Patient 
Clinical Complexity Level, PCCL) can range in value from 0 
up to 4. PCCL calculation is based on an algorithm developed 
by Dr. Xichuan Zhang in the CCL refinement project in Aus-
tralia [17]. Comorbidities and complications (CC) are con-
comitant diagnoses that usually cause higher resource con-
sumption. A total of 3,459 ICD-10 codes have been marked as 
CC in the G-DRG 2010 system. A CCL is allocated to every 
CC, and CCL can have values from 1 to 6. A logarithmic for-
mula combines all CCLs to a calculated value, and after 
rounding the PCCL is available. PCCL is a whole number be-
tween 0 (no comorbidity) and 4 (highest level of comorbid-
ity). PCCL is widely used as a splitting criterion to identify 
cases with higher resource consumption. Usually PCCL levels 
of 4 have to be reached to change the DRG split and to obtain 
a higher remuneration. 
In the field of transfusion medicine, there are numerous di-
agnoses which increase the PCCL level. The number of the 
diagnoses usually used in hemotherapy without a CCL is low. 
From the chapter of nutritional anaemias (D50–D53) only vi-
tamin B12 deficiency anaemias (D51.-) are excluded. Among 
haemolytic anaemias (D55–D59), all diagnoses show a CCL 
except the anaemias due to enzyme disorders (D55) and other 
hereditary haemolytic anaemias (D58). For aplastic anaemias, 
the exclusion list comprises ICD-10 D63.8 (anaemia in other 
chronic diseases classified elsewhere), ICD-10 D64.4 (congen-
ital dyserythropoietic anaemia), ICD-10 D64.8 (other speci-
fied anaemias), and ICD-10 D64.9 (anaemia, unspecified). 
For coagulation defects, purpura, and other hemorrhagic con-
ditions (D65–D69), a CCL has been defined for all diagnoses. 
Thus, all coagulation defects are of PCCL relevance.
As an example, table 3 shows the impact of PCCL 4 on 
DRG remuneration for the field of oncology in which hemo-
therapy is common in the author’s opinion. Whereas the me-
dian remuneration for patients with a PCCL of 0–3 ranges 
around EUR 1,700.00, the rate for the treatment of patients 
(DRG 473, USD 4,427.00). The transfusion costs represented 
a small portion (<1%) of the total hospital costs. Syrjala et al. 
[16] analyzed the transfusion practice in different DRGs in a 
university hospital in Finland. They found that most of the 
DRGs had blood costs but that half of the total costs could be 
found in 13 different DRGs. Among them, acute leukaemia 
(DRG 473) was the most blood consuming with 7.3 RBC and 
45 platelet units transfused per patient (total costs per trans-
fused patient: EUR 3,689.00). Other DRGs with high blood 
consumption were bone marrow transplant (DRG 481), lym-
phoma and non-acute leukaemia (DRG 404), tracheostomy 
(DRG 483), and liver transplant (DRG 480). The depart-
ments with the highest transfusion costs were surgery (39%), 
internal medicine (34%), and paediatrics (19%). For Ger-
many, national data is published on a more aggregate level 
and is more difficult to interpret due to the fact that the need 
for transfusion is not coded by 1 code only. Different codes 
exist depending on the number of transfusion units needed. 
Of the 15,559,359 hospitalizations in Germany in 2007, 
only 116,093 had a principal diagnosis from chapter III of the 
ICD-10 classification (diseases of the blood and blood-form-
ing organs, and certain disorders involving the immune mech-
anism). As discussed in the previous paragraph, the diagnoses 
of chapter III can usually be found in the MDC 16. For all 
other DRGs that are not part of MDC 16, in no case a diagno-
sis from the field of transfusion medicine or a procedure from 
the field of hemotherapy will immediately influence the 
grouper result. Usually, the rationale as to why a distinct 
DRG is targeted is not dependent on whether transfusion 
medicine was necessary or not. This does not mean that trans-
fusion medicine and hemotherapy remain totally unconsid-
ered in the remuneration system beyond MDC 16. To make it 
possible to accent pre-existing medical conditions and con-
comitant complications, 3 major principles have been intro-
duced in the G-DRG system: i) Diagnoses from the field of 
transfusion medicine usually increase the comorbidity and 
complexity level (CCL); ii) Procedures from the field of he-
motherapy can be used in a so-called function which is a pre-
DRG PCCL 0–3  
(remuneration, EUR)
PCCL 4  
(remuneration, EUR)
B66 brain cancer B66D (2,107.00) B66B (3,757.00)
D60 ENT cancer D60C (1,767.00) D60B (2,184.00)
E71 thorax cancer E71B (1,714.00) E71A (3,322.00)
G60 GI cancer G60B (1,162.00) G60A (1,911.00)
H61 pancreas cancer H61B (1,914.00) H61A (3,369.00)
I65 soft tissue cancer I65C (2,322.00) I65B (3,337.00)
J62 breast cancer J62B (1,702.00) J62A (3,349.00)
L62 genitourinary cancer L62B (1,576.00) L62A (3,273.00)
M60 cancer of the male genitals M60C (1,644.00) M60A (3,493.00)
N60 cancer of the female genitals N60B (1,661.00) N60A (3956.00)
ENT = Ear nose throat; GI = gastrointestinal.
Table 3. Examples of the impact of PCCL 4 
on remuneration for oncologic DRGs with 
 conservative treatment such as chemotherapy 
(base rate EUR 2,950.00)
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the hospital. For very rare procedures, however, hospitals can 
negotiate individual ZE prices. For the field of hemotherapy 
and transfusion medicine, fixed price ZE can be found for 
plasmapheresis (ZE 36) and the application of thrombocyte 
concentrates generated by apheresis (ZE 84), thrombocyte 
concentrates (ZE 94), PRC (ZE 107) and patient-specific 
thrombocyte concentrates (ZE 108). ZE with a price that can 
be negotiated by the hospital exist for cell apheresis (ZE2010-
15), the application of granulocyte concentrates (ZE2010-34), 
and the acquisition of hematopoietic stem cells (ZE2010-35). 
Table 5 lists the lowest and the highest price for the named 
procedures. Some procedures are not paid additionally unless 
a minimum amount is administered. For example, for PRC, at 
least 6 PRC have to be given for children under the age of 15 
and at least 16 PRC have to be given for adolescents over 14 
and adults to trigger a ZE remuneration. 
What can be done to improve the remuneration for trans-
fusions in Germany? While, as outlined above, the principle 
tools to document the additional costs are provided within the 
G-DRG system (PCCL and complex constellation as split cri-
terion, ZE), they are probably not used as well as they could 
be. The main problem is the profound and exact documenta-
tion of all costs associated with transfusion. The costs that are 
used to remunerate transfusions in the DRG system are prob-
ably based almost solely on acquisition costs. Infrastructural 
costs for transport and storage and handling of the product 
are likely not associated with the case costs. Furthermore, 
laboratory costs (e.g. cross-matching) and labour costs for 
performing and documenting the transfusion are likely not in-
cluded in the calculation data used by the InEK to calculate 
DRG and ZE. Therefore, every endeavour should be made to 
associate transfusion costs with the case. This can only be 
achieved by close collaboration between the clinical depart-
with a PPCL of 4 will be approximately EUR 3,300.00. Of 
course this duplication of remuneration is not triggered by he-
motherapy and transfusion medicine only, but reflects the 
higher resource consumption for the treatment of these multi-
morbid patients in general. 
Procedures from the field of hemotherapy can trigger a so-
called function that may cause a shift to a more valuable 
DRGs and result in higher remuneration. Functions have very 
complex definitions. To get a function activated, more than 1 
condition must prevail. The most prominent and common 
function in the G-DRG system is the term ‘complex constella-
tion’. For a complex constellation, at least 2 platelet concen-
trates or at least 11 PRC have to be given (condition 1), and 
patients have to undergo mechanical ventilation for >48 h or 
be diagnosed with disseminated intravascular coagulation 
(DIC) or receive specific drainage treatment / pacemaker 
treatment / invasive monitoring / radiation treatment or un-
dergo hemodialysis or resuscitation (condition 2). The exact 
definition of complex constellation lists up over 20 different 
combinations [10]. Table 4 shows the impact of the function 
‘complex constellation’ on DRG remuneration for brain tu-
mours and for DRG A13, a common DRG for patients re-
quiring intensive care with mechanical ventilation for 4–10 
days.Procedures may be remunerated directly by ZE (addi-
tional remuneration fees). The ZE system was introduced in 
2005 after 2 years of testing of the G-DRG. It was observed 
that a major reason for cost variability could be found in spe-
cific expensive items such as implants, drugs, or blood prod-
ucts. By separating these expensive items from the lump sum 
and generating a pricelist for ZE, a much more homogeneous 
cost distribution in the DRG itself could be achieved. ZE 
price lists follow a national standard and are updated annu-
ally. Usually the ZE price is predefined and not negotiable for 
DRG Without complex constellation  
(remuneration, EUR)
With complex constellation  
(remuneration, EUR)
A13 mechanical ventilation  
>95 h and up to <250 h
A13G (10,912.00) A13E (20,134.00)
B66 brain cancer B66D (2,107.00) B66A (8,162.00)
Table 4. Examples of the impact of the func-
tion ‘complex constellation’ on remuneration 
for intensive care DRGs or brain cancer DRGs 
with conservative treatment such as chemo-
therapy (base rate EUR 2,950.00)
ZE Price list range, EUR
ZE 36 plasmapheresis 1,305.00 (×1) – 67,874.00 (> ×49)
ZE 84 thrombocyte concentrate (apheresis) 458.00 (×1) – 55,002.00 (> ×117)
ZE94 thrombocyte concentrate (non-apheresis) 535.00 (×2) – 34,778.00 (> ×127)
ZE107 packed red cells 608.00 (×6) – 22,630.00 (> ×279)
ZE108 thrombocyte concentrate, patient-specific 490.00 (×1) – 35,257.00 (> ×70)
ZE2010–15a cell apheresis 589.00 (×1)
ZE2010–34a granulocyte concentrate 750.00 (×1) – XXX (> ×20)
ZE2010–35a acquisition of stem cells 10,200.00 (Germany) – 25,830.00 (overseas)
aNo national price defined; listed price represents the price list of the author’s institution.
Table 5. Additional remuneration fees (ZE) 
in transfusion medicine and hemotherapy 
showing the lowest and the highest amounts 
paid for national prices in 2010
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duced in 2006. NUBs can be negotiated immediately between 
the hospital willing to use the new innovation and the sick 
fund. An exclusive NUB list is issued annually by the InEK. 
Only procedures listed on this NUB-list can be negotiated, 
after an application to use a specific method/drug has been is-
sued by the individual hospital to the InEK [18]. Table 6 lists 
the NUB candidates from the field of hemotherapy and trans-
fusion medicine in 2010. The NUB principle allows for remu-
neration of a drug or method immediately after its introduc-
tion. For blood products, no NUB currently exists. As only 
new drugs and treatment methods fulfil the requirements of 
NUB, transfusion of traditional blood products (PRC, plate-
lets) does not qualify. One NUB that is associated with trans-
fusion medicine is plerixafor which is used for the collection 
of peripheral blood stem cells in patients failing to respond 
to granulocyte colony-stimulating factor. This new drug has 
been granted NUB status 1, meaning additional remuneration 
can be negotiated with the health insurance funds. The exact 
amount of money paid is also subject to these negotiations. 
Hence, the NUB procedure provides for adequate remunera-
tion for these patients. Patient-specific cellular therapies are 
another example of a transfusion medicine product which is 
new, expensive, and therefore eligible for the NUB process.
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ment, the department of transfusion medicine, and the admin-
istration. Once this has been done, it should be reflected in 
increased DRG remunerations and increased ZE. 
Challenge 3: How Can We Assure that Medical 
Progress Is Rapidly Implemented into Clinical Routine 
and Not Obstructed by Financial Restraints?
The G-DRG system was designed to be adaptive. It is annually 
revised by a cost calculation based on real life cost data. As the 
annual calculation is always based on the treatment data of the 
preceding year and is calculated and published for the subse-
quent year, an inevitable 2-year gap between expenditure and 
remuneration occurs. Innovations that are consumed by the 
hospital in this 2-year period will neither be covered by 
G-DRG lump sums nor by ZE. To bridge this innovation gap, 
the New Diagnostic and Treatment Methods (Neue Untersu-
chungs- und Behandlungsmethoden, NUB) system was intro-
NUB11 romiplostim
NUB32 plerixafor
NUB525 eltrombopaga
aProviso status: information for a full assess-
ment of this method was insufficient.
Table 6. Candidates 
for a NUB (New 
 Diagnostic and Treat-
ment Methods) fee 
relevant to hemo-
therapy and transfu-
sion medicine in 2010
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